New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
| Autor: | Philip A. Routledge, Alice Varnava, Robert Bracchi, Dyfrig A. Hughes, Karen Samuels |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Technology Assessment Biomedical Time Factors media_common.quotation_subject Cost-Benefit Analysis Advisory Committees Decision Making MEDLINE Nice Health administration 03 medical and health sciences 0302 clinical medicine Excellence medicine Humans 030212 general & internal medicine Original Research Article Duration (project management) health care economics and organizations computer.programming_language media_common Pharmacology Health economics Wales business.industry 030503 health policy & services Health Policy Public health Public Health Environmental and Occupational Health Health technology United Kingdom Scotland Family medicine Practice Guidelines as Topic 0305 other medical science business computer |
| Zdroj: | Pharmacoeconomics |
| ISSN: | 1179-2027 1170-7690 |
| Popis: | Background The All Wales Medicines Strategy Group (AWMSG) develops prescribing advice and is responsible for appraising new medicines for use in Wales. In this article, we examine the medicines appraisal process in Wales, its timeliness and its impact on medicines availability in Wales, and compare its processes and recommendations with the two other UK health technology appraisal bodies [the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)]. Methods We reviewed the medicines appraisals conducted by AWMSG between October 2010 and September 2015. The duration of the process and the recommendations made by AWMSG were compared with those of NICE and SMC. Only publicly available data were considered in this review. Results AWMSG conducted 171 single technology appraisals for 137 medicines during the study period (34 were for medicines previously appraised by AWMSG but these were for new indications). Of these, 152 appraisals were supported for use in NHS Wales (33 with restrictions) and 19 were not supported. Recommendations broadly concurred with SMC and NICE for the majority of appraisals. Compared with NICE recommendations, the median time advantage gained in Wales for those medicines that received a positive AWMSG recommendation and which were subsequently superseded by NICE advice was 10.6 months (range 3.5–48.3 months; n = 17). Conclusion This review highlights the work carried out by AWMSG over a 5-year period, and provides evidence to support the effectiveness of the appraisal process in terms of patients in Wales gaining earlier access to medicines and efficiency through reduced duplication with NICE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink